Biology Reference
In-Depth Information
Martorana PA, Beume R, Lucattelli M, Wollin L, Lungarella G (2005) Roflumilast fully prevents
emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med
172:848-853
Martorana PA, Lunghi B, Lucattelli M, de Cunto G, Beume R, Lungarella G (2008) Effect of
roflumilast on inflammatory cells in lungs of cigarette smoke-exposed mice. BMC Pulm Med
8:17-26
Mata M, Sarri´ B, Buenestado A, Cortijo J, Cerd´ M, Morcillo EJ (2005) Phosphodiesterase
4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human
airway epithelial cells. Thorax 60:144-52
Maurice DH, Haslam RJ (1990) Molecular basis of synergistic inhibition of platelet function by
nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by
cyclic GMP. Mol Pharmacol 37:671-681
May CD (1974) History of the introduction of theophylline into the treatment of asthma. Clin
Allergy 4:211-217
Milara J, Cortijo J, Armengot M, Banuls P, Gabarda E, Morcillo E (2008a) Effect of roflumilast, a
PDE4 inhibitor on ciliary beat frequency in human nasal epithelial cells. Eur Respir J Suppl
639s:P3651
Milara J, Cortijo J, Mata M, Donet E, Mauricio M, Morcillo EJ (2008b) The PDE4 inhibitor
roflumilast N-oxide partly reversed TGFß1-induced changes in collagen I and E-cadherin
expression in human airway epithelial cells. Eur Respir J (Suppl) 639s:P3648, abstract
Morley J, Sanjar S, Page CP (1984) Platelet activation as a basis for asthma exacerbation. Lancet
2:1142-1144
Murray JL, Lopez AD (1997) Alternative projections of mortality and disability by cause
1990-2020: global burden of disease study. Lancet 349:1498-1504
Muzaffar S, Shukla N, Angelini GD, Jeremy JY (2008). Roflumilast N-oxide inhibits NADPH
oxidase expression and activity in human pulmonary artery smooth muscle cells; Proc Br
Pharmacol Soc 027P, (abstract).
Naline E, Qian Y, Advenier C, Raeburn D, Karlsson J-A (1996) Effects of RP 73401, a novel,
potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated
bronchial muscle. Br J Pharmacol 118:1939-1944
Nicholson CD, Jackman SA, Wilke R (1989) The ability of denbufylline to inhibit cyclic
nucleotide phosphodiesterase and its affinity for adenosine receptors and the re-uptake site.
Br J Pharmacol 97:889-897
Nicholson CD, Challiss RAJ, Shahid M (1991) Differential modulation of tissue function and
therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.
Trends Pharmacol Sci 12:19-27
Nielson CP, Vestal RE, RJ S, Heaslip R (1990) Effects of selective phosphodiesterase inhibitors on
the polymorphonuclear leukocyte respiratory burst. J Alllergy Clin Immunol 86:801-808
O'Connolly M, Dierdorf D, Greb WH, Mayer M-ER, Wolf D (1988) Efficacy of denbuffylline in
patients with multi-infarct dementia. Dru Dev Res 14:195-198
Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong N-S (2004) A prospective
clinical study of
theophylline safety in 3810 elderly with asthma or COPD. Respir
Med 98:1016-1024
Orange RO, Austen WG, Austen KF (1971) Immunological release of histamine and slow-reacting
substance of anaphylaxis from human lung. J Exp Med 134:136-148
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH,
Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tendon PK,
DeMets DL (1991) Effect of oral milrinone on mortality in severe heart failure. N Engl
J Med 3325:1468-1475
Pedemonte N, Galietta L (2008). Stimulation of CFTR-dependent chloride secretion by roflumi-
last. Eur Respir J Suppl 644s:P3672.
Persson CG (1985) On the medical history of xanthines and other remedies for asthma: a tribute to
HH Salter. Thorax 40:881-886
